Prot #BTTC12-01: NU MD13C04: A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab

  • Raizer, Jeffrey J (PD/PI)

Project: Research project

Project Details

Effective start/end date7/16/147/16/17


  • University of Texas M. D. Anderson Cancer Center (Prot #BTTC12-01)
  • GlaxoSmithKline LLC (Prot #BTTC12-01)